Table of Content

1 Markets: Industry Outlook 
1.1        Trends: Current and Future Impact Assessment
             1.1.1            Usage of AI/ML to Accelerate Drug Development
             1.1.2            Growing Emphasis on Developing Biosimilars and Biobetters
             1.1.3            Shift Towards Targeted and Precision Medicine
1.2        Supply Chain Overview
             1.2.1            Value Chain Analysis
1.3        R&D Review
             1.3.1            Patent Filing Trend by Country, by Company
1.4        Regulatory Landscape
1.5        Impact Analysis COVID-19
1.6        Market Dynamics Overview
             1.6.1            Market Drivers
             1.6.2            Market Restraints
             1.6.3            Market Opportunities

2 Application
2.1 Application Segmentation
2.2 Application Summary
2.3 Global Biological Drug Discovery Market (by Method)
2.3.1 Target Identification/ validation
2.3.2 Hit Generation/ Validation
2.3.3 Lead Identification
2.3.4 Lead Optimization
2.4 Global Biological Drug Discovery Market (by Manufacture Type)
2.4.1 In-House Manufacturing
2.4.2 Outsourced Manufacturing

3 Product
3.1 Product Segmentation
3.2 Product Summary
3.3 Global Biologics Drug Discovery Market (by Type)
3.3.1 Monoclonal Antibodies
3.3.1.1 Global Monoclonal Antibodies by Method
3.3.1.1.1 Target Identification/ Validation
3.3.1.1.1.1 Functional Genomics/Proteomics
3.3.1.1.1.2 Cell-based Assay
3.3.1.1.1.3 CRISPR/Knockout Studies/Cas9
3.3.1.1.1.4 Animal/Disease Based Models
3.3.1.1.1.5 Computational/in-Silico/Bioinformatics
3.3.1.1.2 Hit Generation/ Validation
3.3.1.1.2.1 mAb Sequencing
3.3.1.1.2.2 Hybridoma Screening
3.3.1.1.2.3 Customized Synthetic Library Screening
3.3.1.1.2.4 Phase Display Screening
3.3.1.1.2.5 High-Throughput Screening
3.3.1.1.2.6 Others
3.3.1.1.3 Lead Identification
3.3.1.1.3.1 Phase Display
3.3.1.1.3.2 ELISA/ADCC & CDC Assay
3.3.1.1.3.3 Array-Based Screening
3.3.1.1.3.4 Hybridoma Screening and Humanization
3.3.1.1.3.5 Bioanalytical Analysis
3.3.1.1.3.6 Others Assays
3.3.1.1.4 Lead Optimization
3.3.1.1.4.1 Humanization
3.3.1.1.4.2 Affinity Analysis
3.3.1.1.4.3 Protein Engineering
3.3.1.1.4.4 In-Vitro/In-Vivo efficacy Assays
3.3.1.1.4.5 Others
3.3.2 Recombinant Proteins
3.3.2.1 Global Protein Recombinant by Method
3.3.2.1.1 Target Identification/ Validation
3.3.2.1.1.1 Functional Genomics/Proteomics
3.3.2.1.1.2 Cell-based Assay
3.3.2.1.1.3 CRISPR/Knockout Studies/Cas9
3.3.2.1.1.4 Animal/Disease Based Models
3.3.2.1.1.5 Computational/in-Silico/Bioinformatics
3.3.2.1.2 Hit Generation/ Validation
3.3.2.1.2.1 mAb Sequencing
3.3.2.1.2.2 Hybridoma Screening
3.3.2.1.2.3 Customized Synthetic Library Screening
3.3.2.1.2.4 Phase Display Screening
3.3.2.1.2.5 High-Throughput Screening
3.3.2.1.2.6 Others
3.3.2.1.3 Lead Identification
3.3.2.1.3.1 Phase Display
3.3.2.1.3.2 ELISA/ADCC & CDC Assay
3.3.2.1.3.3 Array-Based Screening
3.3.2.1.3.4 Hybridoma Screening and Humanization
3.3.2.1.3.5 Bioanalytical Analysis
3.3.2.1.3.6 Others Assays
3.3.2.1.4 Lead Optimization
3.3.2.1.4.1 Humanization
3.3.2.1.4.2 Affinity Analysis
3.3.2.1.4.3 Protein Engineering
3.3.2.1.4.4 In-Vitro/In-Vivo efficacy Assays
3.3.2.1.4.5 Others
3.3.3 Other Biologics

4 Region
4.1 Regional Summary
Table: Biologics Drug Discovery Market, By Region, ($ Million), 2022-2033
4.2 Drivers and Restraints
4.3 North America
Key Market Participants in North America
Business Drivers
Business Challenges
4.3.1 Application
Table: North America Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3.2 Product
Table: North America Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
4.3.3 North America (by Country)
4.2.4.1 U.S.
Table: U.S. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.2.4.2 Canada
Table: Canada Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3 Europe
4.3.1 Key Market Participants in Europe
4.3.2 Business Drivers
4.3.3 Business Challenges
4.3.4 Application
Table: Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3.3 Product
Table: Europe Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
4.3.4 Europe (by Country)
4.3.4.1 France
Table: France Biologics Drug Discovery Market, By Manufacture Tyoe ($ Million), 2022-2033
4.3.4.2 Germany
Table: Germany Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3.4.3 U.K.
Table: U.K. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3.4.4 Switzerland
Table: Swizterland Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.3.4.5 Rest-of-Europe
Table: Rest-of Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4 Asia-Pacific
4.4.1 Key Market Participants in Asia-Pacific
4.4.2 Business Drivers
4.4.3 Business Challenges
4.4.2 Application
Table: Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4.3 Product
Table: Asia-Pacific Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
4.4.4 Asia-Pacific (by Country)
4.4.4.1 China
Table: China Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4.4.2 India
Table: India Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4.4.3 Japan
Table: Japan Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4.4.4 Australia
Table: Australia Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.4.4.5 Rest-of-Asia-Pacific
Table: Rest-of-Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.5 Rest-of-the-World
4.5.1 Key Market Participants in Rest-of-the-World
4.5.2 Business Drivers
4.5.3 Business Challenges
4.5.4 Application
Table: Rest-of-the-World Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
4.5.4 Product
Table: Rest-of-the-World Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
5 Markets - Competitive Landscape & Company Profiles
5.1 Competitive Landscape
5.2 Company Profile
5.2.1 AbbVie, Inc.
5.2.1.1 Company Overview
5.2.1.2 Product Portfolio
5.2.1.3 Analyst View
5.2.2 Amgen, Inc.
5.2.2.1 Company Overview
5.2.2.2 Product Portfolio
5.2.2.3 Analyst View
5.2.3 Astellas Pharma, Inc.
5.2.3.1 Company Overview
5.2.3.2 Product Portfolio
5.2.3.3 Analyst View
5.2.4 AstraZeneca, Plc
5.2.4.1 Company Overview
5.2.4.2 Product Portfolio
5.2.4.3 Analyst View
5.2.5 Bayer AG
5.2.5.1 Company Overview
5.2.5.2 Product Portfolio
5.2.5.3 Analyst View
5.2.6 Bicon Ltd.
5.2.6.1 Company Overview
5.2.6.2 Product Portfolio
5.2.6.3 Analyst View
5.2.7 Boehringer Ingelheim GmbH
5.2.7.1 Company Overview
5.2.7.2 Product Portfolio
5.2.7.3 Analyst View
5.2.8 Bristol-Myers Squibb Company
5.2.8.1 Company Overview
5.2.8.2 Product Portfolio
5.2.8.3 Analyst View
5.2.9 Eli Lily and Company
5.2.9.1 Company Overview
5.2.9.2 Product Portfolio
5.2.9.3 Analyst View
5.2.10 F.Hoffmann-La Roche AG
5.2.10.1 Company Overview
5.2.10.2 Product Portfolio
5.2.10.3 Analyst View
5.2.11 GenScript
5.2.11.1 Company Overview
5.2.11.2 Product Portfolio
5.2.11.3 Analyst View
5.2.12 Gilead Sciences, Inc.
5.2.12.1 Company Overview
5.2.12.2 Product Portfolio
5.2.12.3 Analyst View
5.2.13 GlaxoSmithKline, Plc
5.2.13.1 Company Overview
5.2.13.2 Product Potfolio
5.2.13.3 Analyst View
5.2.14 Johnson and Johnson
5.2.14.1 Company Overview
5.2.14.2 Product Potfolio
5.2.14.4 Analyst View
5.2.15 Laboratory Corporation of America Holdings
5.2.15.1 Company Overview
5.2.15.2 Product Potfolio
5.2.15.3 Analyst View
5.2.16 Merck KGaA
5.2.16.1 Company Overview
5.2.16.2 Product Potfolio
5.2.16.4 Analyst View
5.2.17 Novartis AG
5.2.17.1 Company Overview
5.2.17.2 Product Potfolio
5.2.17.3 Analyst View
5.2.18 Novo Nordisk
5.2.18.1 Company Overview
5.2.18.2 Product Potfolio
5.2.18.3 Analyst View
5.2.19 Pfizer
5.2.19.1 Company Overview
5.2.19.2 Product Potfolio
5.2.19.3 Analyst View
5.2.20 Sanofi
5.2.20.1 Company Overview
5.2.20.2 Product Potfolio
5.2.20.3 Analyst View
5.2.21 Teva Pharmaceutical Industries, Ltd.
5.2.21.1 Company Overview
5.2.21.2 Product Potfolio
5.2.21.3 Analyst View